| Bioactivity | ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3]. |
| Invitro | ZLc-002 (1 μM; 24 h) inhibits nNOS-CAPON in cultured hippocampal neurons from ICR mice[3]. Cell Viability Assay[3] Cell Line: |
| In Vivo | ZLc-002 (30 mg/kg; i.p. from 4-10 days until 46 days after stroke everyday) improves motor function in tMCAO mice[1].ZLc-002 (40 mg/kg; i.v. once per day for seven days) improves chronic mild stress (CMS)-induced anxiety-related behaviours[2].ZLc-002 (10 μM 1 μL; hippocampus injection once per day for seven days) improves corticosterone (CORT)-induced anxiety-related behaviours[2]. Animal Model: |
| Name | ZLc-002 |
| CAS | 1446971-41-0 |
| Formula | C10H17NO5 |
| Molar Mass | 231.25 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase)-CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50(3):728-737. [2]. Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177(16):3674-3690. [3]. Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20(9):1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17. |